Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry

  • Cervera R
  • Espinosa G
  • Bucciarelli S
 et al. 
  • 15


    Mendeley users who have this article in their library.
  • 24


    Citations of this article.


Although less than 1% of patients with the antiphospholipid syndrome (APS) develop the catastrophic variant, its potentially lethal outcome emphasizes its importance in clinical medicine today. However, the rarity of this variant makes it extraordinarily difficult to study in any systematic way. In order to put together all the published case reports as well as the new diagnosed cases from all over the world, an international registry of patients with catastrophic APS ("CAPS Registry") was created in 2000 by the European Forum on Antiphospholipid Antibodies. Currently, it documents the entire clinical, laboratory and therapeutic data of more than 300 patients whose data has been fully registered. This registry can be freely consulted at the Internet (www.med.ub.es/MIMMUN/FORUM/CAPS.HTM) and it is expected that the periodical analysis of these data will allow us to increase our knowledge of this condition. © 2006 Elsevier B.V. All rights reserved.

Author-supplied keywords

  • Anticardiolipin antibodies
  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Catastrophic antiphospholipid syndrome
  • Lupus anticoagulant

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Ricard Cervera

  • Gerard Espinosa

  • Silvia Bucciarelli

  • José A. Gómez-Puerta

  • Josep Font

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free